INmune Bio Inc. Share Price & Technical Analysis
INMB · $1.45 (+0.69%)
Healthcare / Biotechnology
$1.45
+0.69%
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patie…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
0% return in May, -7% avg return in past 3 year May month.
6% return in 2026, -5% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | -13% | -8% | 27% | 0% | – | – | – | – | – | – | – | 6% |
| 25 | 117% | -18% | -4% | 1% | -6% | -69% | 29% | -23% | 5% | -14% | -6% | -6% | 5% |
| 24 | 7% | -3% | 2% | 0% | -22% | -8% | -3% | -23% | -18% | 7% | -14% | -8% | -82% |
| 23 | 26% | 9% | -30% | 11% | 6% | 14% | -7% | -6% | -17% | 7% | 29% | 19% | 61% |
| 22 | -3% | -13% | -3% | -12% | -8% | 24% | 1% | -11% | -19% | 20% | -4% | -11% | -39% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$36.42M
P/E ratio
—
52W high
$11.64
52W low
$1.09
Volume
1,70,504
Beta
1.05
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is INmune Bio Inc. share price today?
- INmune Bio Inc. (INMB) last traded around $1.45 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INMB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INMB. Download the app for real-time alerts.
- How can I analyze INmune Bio Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.